Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-Galmydar PET/CT for Myocardial Perfusion Imaging
NCT05625490Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ga-68 Galmydar in coronary artery disease (CAD) (3 arms), sponsored by Washington University School of Medicine. Primary endpoint: Semiquantitative assessment of 68Ga-Galmydar PET/CT uptake. Started Nov 2022; status: completed.
02
Drugs
Ga-68 Galmydar
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05625490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625490.